Codexis, Inc. (CDXS)
Chart Events
Performance Outlook
| Previous Close | 21.86 |
| Open | 22.13 |
| Bid | 21.97 x 800 |
| Ask | 22.00 x 1100 |
| Day's Range | 21.71 - 22.50 |
| 52 Week Range | 10.31 - 29.56 |
| Volume | 262,821 |
| Avg. Volume | 522,492 |
| Market Cap | 1.415B |
| Beta (5Y Monthly) | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.42 |
| Earnings Date | Aug 04, 2021 - Aug 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.50 |
Fair Value
Related Research
- GlobeNewswire
Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder
REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, today announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for the research and development of an additional gene therapy for a lysosomal storage disorder bringing the total number of programs under the agreement to four. Under the terms of the original March 2020 agreem
- Insider Monkey
10 Best Cheap Tech Stocks to Buy According to Cathie Wood
In this article we discuss the 10 best tech stocks to buy according to Cathie Wood. If you want to read our detailed analysis of Wood’s history, and hedge fund performance, go directly to the 5 Best Cheap Tech Stocks to Buy According to Cathie Wood. Catherine Wood, the legendary investor who runs ARK Investment […]
- GlobeNewswire
Codexis to Participate in Upcoming Virtual Healthcare Conferences
REDWOOD CITY, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in three upcoming virtual investment conferences. The Jefferies Virtual Healthcare Conference – June 1, 2021 at 4:30 p.m. ET a live webcast of the fireside chat presentation will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com. A replay of the webcast will be archived for 30 days following the event.The Craig-Hallum Institutional Investor Conference – June 2, 2021, management will attend and host 1x1 investor meetings.The Piper Sandler SynBio Day – June 23, 2021, management will participate in a panel discussion. About CodexisCodexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company’s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit www.codexis.com. Forward-Looking StatementsTo the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause Codexis’ future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Codexis undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Codexis’ business in general, please refer to Codexis’ prospectus supplement to be filed with the Securities and Exchange Commission (“SEC”), including the documents incorporated by reference therein, which include Codexis’ Annual Report on Form 10-K filed with the SEC on March 1, 2021, Codexis’ Quarterly Report on Form 10-Q filed with the SEC on May 7, 2021, and Codexis’ other periodic reports filed with the SEC. Investor Relations Contact:Argot PartnersStephanie Marks/Carrie McKim(212) 600-1902Codexis@argotpartners.com
